A norovirus vaccine could be on the horizon as cases rise

Core Insights - Moderna is developing a vaccine for norovirus, with a large phase three trial currently underway, and results expected as early as late 2024 or 2026 [2][10] - The current winter has seen a significant increase in norovirus cases, with a 36% rise in outbreaks compared to the previous season, and twice as many positive tests reported in January [4][3] - The vaccine candidate targets three genotypes of norovirus, but does not include the genotype responsible for most infections this year [5][6] Company Strategy - The primary goal of the vaccine is not to completely prevent norovirus but to reduce the severity of symptoms and prevent hospital visits [7] - The company aims to vaccinate vulnerable populations, particularly seniors aged 65 and above, who are at higher risk of complications from norovirus [8] - Other target groups include healthcare workers, daycare workers, and individuals on cruise ships, as these populations are frequently exposed to norovirus [9][10] Market Considerations - Investors are skeptical about the commercial viability of the vaccine, contingent on its effectiveness, with a focus on protecting those in nursing homes and cruise passengers [10] - The vaccine is not currently being tested in children, but if successful in adults, further studies in children will be necessary [10]